Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

BACKGROUND: The incidence of renal cell cancer (RCC) has been increasing for the past decade, and the 5-year survival for patients with metastatic RCC (mRCC) is rather low. Everolimus (RAD001), a new inhibitor for mammalian target of rapamycin (mTOR), is generally well tolerated, and demonstrates cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siming, Kong, Yan, Si, Lu, Chi, Zhihong, Cui, Chuanliang, Sheng, Xinan, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041340/
https://www.ncbi.nlm.nih.gov/pubmed/24886512
http://dx.doi.org/10.1186/1471-2407-14-376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041340/
https://www.ncbi.nlm.nih.gov/pubmed/24886512
http://dx.doi.org/10.1186/1471-2407-14-376

Ejemplares similares